We are a biopharmaceutical company specializing in two high-growth markets: assisted reproductive drugs and ophthalmic drugs. Targeting unmet clinical needs, we have built a comprehensive R&D system and internal production capabilities at a commercial scale. Leveraging these resources, we have independently developed a diverse product pipeline and advanced several high-tech, commercially promising drug candidates in both fields to late-stage clinical trials and the commercialization stage.
Our founder and CEO, Dr. Peng Hongwei, brings over 30 years of experience in biopharmaceutical R&D. He has achieved outstanding accomplishments in the biopharmaceutical industry and received various awards, including the first prize of Sichuan Provincial Science and Technology Progress Award, the first prize of National Science and Technology Progress Award, being named as a Team Leader Talent of Innovation and Entrepreneurship of Jiangsu Province, being selected for the Sichuan Provincial “Thousand Talents Plan” Recruitment Program of Global Experts in 2018, and being recognized as a Zhangjiang National Innovation Demonstration Zone Outstanding Innovative and Entrepreneurial Talent in 2021. Dr. Peng spearheaded the development of the national Category 1 biologic new drug, recombinant human brain natriuretic peptide(brand name: Xinhuosu® (新活素®)),which received market approval in 2005. The product has remained as a unique offering in the domestic market for nearly 20 years and has been recommended as a first-line treatment in the National Acute Heart Failure Treatment Guidelines. His proven leadership and successful track record in guiding innovative biopharmaceutical products from early development to commercialization provide a strong foundation for our success.
